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Abstract
Background: Human papillomaviruses (HPVs) remain a serious world health problem due to their association with
anogenital/oral cancers and warts. While over 100 HPV types have been identified, a subset is associated with
malignancy. HPV16 and 18 are the most prevalent oncogenic types, while HPV6 and 11 are most commonly
responsible for anogenital warts. While other quantitative PCR (qPCR) assays detect oncogenic HPV, there is no
single tube assay distinguishing the most frequent oncogenic types and the most common types found in warts.
Results: A Sybr Green-based qPCR assay was developed utilizing degenerate primers to the highly conserved HPV
E1 theoretically detecting any HPV type. A single tube multiplex qPCR assay was also developed using type-specific
primer pairs and TaqMan probes that allowed for detection and quantitation of HPV6,11,16,18. Each HPV type was
detected over a range from 2 × 101 to 2 × 106copies/reaction providing a reliable method of quantitating type-
specific HPV in 140 anogenital/cutaneous/oral benign and malignant specimens. 35 oncogenic and low risk alpha
genus HPV types were detected. Concordance was detected in previously typed specimens. Comparisons to the
gold standard detected an overall sensitivity of 89% (95% CI: 77% - 96%) and specificity of 90% (95%CI: 52% - 98%).
Conclusion: There was good agreement between the ability of the qPCR assays described here to identify HPV
types in malignancies previously typed using standard methods. These novel qPCR assays will allow rapid detection
and quantitation of HPVs to assess their role in viral pathogenesis.
Background
Papillomaviridae comprise a diverse family of non-envel-
oped, small circular double-stranded DNA viruses, cap-
able of infecting mammals and birds [1]. In humans
these viruses cause pathologies that range from benign
warts to malignant cancer. It is now accepted that HPV
is the causative agent of more than 90% of all cervical
cancers [2]. HPV has also been found to be associated
with anal cancer [3] and anogenital warts [4]. There is
increasing evidence that HPV is associated with head
and neck squamous cell carcinoma unrelated to smok-
ing and/or alcohol consumption [5-7].
HPV types are divided into low- and high-risk groups
with regards to their association with malignancy [8].
Low-risk HPV types 6 and 11 are most commonly
detected in genital and anal warts, representing 90% of
these cases [4]. Oncogenic HPV types 16 and 18
account for 70% of HPV-related cervical cancers. An
increase in HPV viral loads has been correlated with dis-
ease progression in cervical cancer [9]. Similarly, ele-
vated HPV viral loads were detected in HPV16-
associated oropharyngeal squamous cell carcinomas
[10]. These aforementioned associations highlight the
importance of detecting, distinguishing, and quantitating
both low risk and oncogenic HPV infections for moni-
toring and treating disease development and progression
[9,10].
PCR represents a sensitive method for the detection of
HPV DNA. Currently, standard nested HPV PCR can be
performed using degenerative primers followed by direct
sequencing of the PCR product. Alternatively, PCR pro-
ducts can be hybridized to DNA of known HPV types,
to determine the type of HPV present in the PCR-
amplified sample (e.g. Roche HPV Amplicor system).
Both assays are time consuming and do not allow for
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the quantitation of viral DNA to address the role of viral
load in disease progression.
Real time quantitative PCR (qPCR) allows for quanti-
tation of DNA over 8 orders of magnitude [11]. While
qPCR assays have been developed for HPV16 and/or 18
[12-16] relatively little has been done to develop assays
that are capable of detecting other HPV types. Recently,
two qPCR assays have been described that have
increased the types of HPV that can be quantitatively
detected [17,18]. In one assay, molecular beacon probes
were used to distinguish low risk and oncogenic HPV
types in a single multiplex reaction [18] although it did
not allow for the specific determination of the HPV
type. In another assay, TaqMan probes were designed to
detect HPV16, HPV31, HPV 18/45 or HPV33/53/58/67
[17] in two separate multiplex reactions, did not allow
the distinction between HPV33, 52, 58 or 67 and was
unable to differentiate HPV18 from 45. More recently, a
multiplex qPCR assay has been described that can quan-
titatively detect 7 oncogenic HPV types [19]. The assay
is comprised of 2 reactions that detect only oncogenic
HPV and no low risk HPVs. Thus, a single tube, multi-
plex reaction that can recognize common low and onco-
genic HPV types involved in disease would be
advantageous to the monitoring and detection of HPV
infection. This would minimize reagents as well as
decrease the chance for error that is inherent in per-
forming multiple single or multiplex reactions.
This report describes two real time qPCR assays that
can be used in tandem for detection of both common
and uncommon HPV infection. Many distinct HPV
types have been associated with disease hence, the first
qPCR assay is a degenerate assay that targets the HPV
E1 region of known HPVs and should allow for detec-
tion of any of these types. The second qPCR assay tar-
gets the coding region of the hypervariable loop V of
the L1 gene of HPV6, 11, 16 and 18. These HPV types
are associated with the majority of HPV related disease
and are represented in the currently available quadriva-
lent vaccine. The primers and probes used in the devel-
opment of the assay were designed to target and
differentiate between these HPV types. In initial studies
the vaccine has proven effective for prophylaxis against
the initial infection by these types of HPV [20,21]. Vac-
cine efficacy has been assessed by either cytology and/or
qualitative PCR. The qPCR assays described in this
study will provide a more efficient quantitative means of
monitoring of HPV types in populations vulnerable to
HPV-associated disease.
Materials and methods
Subjects
This study was approved by the School of Medicine,
Institutional Review Board University of North Carolina,
Chapel Hill (IRB# 05-DENT-1263-ORC). Study subjects
were identified through the UNC Healthcare Cancer
Registry of >22,000 cases (1995-present). This Registry
maintains a database of all patients diagnosed and/or
treated for malignant neoplasm’s at UNC Healthcare.
Cases were subjects with a histologically-diagnosed can-
cer (confirmed by two independent pathologists). Well-
characterized HPV positive controls from skin and ano-
genital lesions were provided by Joel Palefsky. For gyne-
cological samples, cells were obtained after cervical
lavage from HIV-positive subjects (IRB# 2080-05). Con-
trols were chosen based on biopsies histologically-con-
firmed as benign. Paraffin embedded benign control
tissues were defined as those not demonstrating any
properties associated with malignancy (i.e. mitotic fig-
ures, hyperchromasia, pleomorphism and increased
nuclear/cytoplasmic ratio).
Isolation of cellular genomic DNA
CaSki and HeLa cell genomic DNA was obtained from
Advanced Biotechnologies Inc. SiHA and DG-75 cellular
DNA was isolated from cells using a Qiagen DNeasy Kit
and used as positive controls in the real time PCR assay.
Paraffin-embedded patient tissue was deparaffinized
with xylene. Tissue was washed twice with 100% ethanol
and dried. DNA was isolated using a Qiagen DNeasy kit
according to the manufacturer’s instructions.
Cloning of HPV16 and 18 L1 amplicon
The 136 bp HPV16 L1 amplicon (6605-6741) was PCR-
amplified from CaSki cell genomic DNA using Taq
polymerase and standard PCR conditions. The 120 bp
HPV18 L1 amplicon (6587-6707) was PCR-amplified
from HeLa cell genomic DNA using Taq polymerase
and standard PCR conditions. Both HPV16 L1 and
HPV18 L1 amplicons were TA-cloned into pCR2.1-topo
vector (Invitrogen) according to the manufacturer’s
instructions to obtain the plasmids, pHPV16L1 and
pHPV18L1, respectively. Purified plasmids were
sequenced to verify that the correct sequence was pre-
sent and used to derive standard curves in the real time
PCR assay for the detection of HPV16 and 18 L1 ampli-
cons. Full-length HPV16 genome was PCR-amplified
from Caski cell DNA using a Roche Expand Long Tem-
plate PCR System and the primers HPV16BamHIF (5′-
CCCGGATCCCCATGTACCAATGTTGCA-3′) and
HPV16BamHIR (5′-CCCGGATCCTTTGCCCCAGTG
TTCC-3′). The 7.9 kb PCR fragment was TA-cloned
into pCR2.1-topo vector to generate pHPV16. The plas-
mids pHPV6 and pHPV11 containing the entire genome
of HPV6 and HPV11, respectively, were obtained from
the American Type Culture Collection (ATCC) and
were used to derive standard curves for HPV6 and 11 in
the real time PCR assay.
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Sybr Green Real Time PCR
Real time PCR reactions that target the E1 region of
HPV were performed using Roche Lightcycler Sybr
Green master mix. Each reaction consisted of 1X Roche
Lightcycler Sybr Green master mix, HPVE1F and
HPVE1R (Table 1) in a 10 μl reaction. Regions of high
homology between different types of HPV were identi-
fied with Vector NTI software (Invitrogen) and used to
design degenerative “broad spectrum” HPV primers.
Thermal cycle conditions consisted of an initial dena-
turation incubation at 95°C for 10 minutes followed by
50 cycles of alternating 95°C incubations for 10 seconds,
50°C incubations for 10 seconds and 72°C incubations
for 30 seconds. Fluorescence was detected after every
72°C extension incubation. For standard curves, real
time PCR was performed on a 10-fold dilution series of
purified plasmids, pHPV6, pHPV11 and pHPV16, ran-
ging from 2 × 101 to 2 × 106 copies/reaction.
Sequencing of PCR products
To sequence products generated by the Sybr-green-
based qPCR assay, 3 microliters of ExoSAP-IT (USB
Corporation) was added to 7 microliters of positive reac-
tions. Reactions were incubated at 37°C for 15 minutes
followed by incubation at 80° for 15 minutes. The entire
volume was used for DNA sequencing using HPVE1F as
a sequencing primer (Eton Bioscience Inc.). Blast
sequence analysis was performed on generated
sequences to identify homologies with other known
HPV DNA.
TaqMan Real time PCR reaction
Real time PCR reactions were performed using Roche
Lightcycler TaqMan master mix. Each reaction consisted
of 1X Roche Lightcycler TaqMan master mix, HPV spe-
cific primer pairs and fluorescently-tagged probes for
types 6, 11, 16 and 18 in a total reaction volume of
10 μl (Table 1). The human ApoB (HAPB) gene is
detected at a single copy in normal cells. Primers and
probe targeting the cellular apoB gene as described by
Sanchez and Storch [22] were included in the reactions
to assess DNA integrity. Reactions were performed
using a Roche Lightcycler 480 thermal cycler utilizing a
384 well block. Thermal cycle conditions consisted of an
initial denaturation incubation at 95°C for 10 minutes
followed by 40 cycles of alternating 95°C incubations for
15 seconds and 60°C incubations for 30 seconds. Fluor-
escence was detected after every 60°C extension incuba-
tion. For standard curves, real time PCR was performed
on a 10-fold dilution series of each purified plasmid
containing a type-specific L1 amplicon ranging from 2 ×
101 to 2 × 106 copies/reaction. Quantitation of PCR pro-
ducts was performed using Roche Lightcycler 480 soft-
ware. Color compensation was turned on in all assays to
subtract bleed through between adjacent channels used
to detect specific fluorescent tags.
Statistical Analysis
Sensitivity and specificity were calculated as the propor-
tion of true positives and true negatives, respectively, as
found by the E1 broad spectrum/HPV 6,11,16,18
Table 1 Sequence of HPV type-specific L1 primers and probes used for qPCR
Oligonucleotide Sequence (5’!3’) Concentration/Rx
HPV6L1F TGGGGTAATCAACTGTTTGTTACTGTGGTA 400 nM
HPV6L1R GCATGTACTCTTTATAATCAGAATTGGTGTATGTG 400 nM
HPV6L1probe Cy5-GACATTATGTGCATCCGTAACTAC-BHQ2 200 nM
HPV11L1F CTGGGGAAACCACTTGTTTGTTACTGTG 400 nM
HPV11L1R CGCATGTATTCCTTATAATCTGAATTAGTGTATGTA 400 nM
HPV11L1probe TexasRed-GACACTATGTGCATCTGTGTCTAA-BHQ1 800 nM
HPV16L1F TTGTTGGGGTAACCAACTATTTGTTACTGTT 400 nM
HPV16L1R CCTCCCCATGTCTGAGGTACTCCTTAAAG 400 nM
HPV16L1probe 6FAM-GTCATTATGTGCTGCCATATCTACTTC-TAMRA 400 nM
HP18L1F GCATAATCAATTATTTGTTACTGTGGTAGATACCACT 400 nM
HP18L1R GCTATACTGCTTAAATTTGGTAGCATCATATTGC 400 nM
HPV18L1probe HEX-AACAATATGTGCTTCTACACAGTCTCCTGT-BHQ2 100 nM
HPVE1F1 ANANGCTGTGCAKGNNCTAAAACGAAG 300 nM
HPVE1R1 AGTTTCCACTTCAGTATTGCCATA 300 nM
HAPBF TGAAGGTGGAGGACATTCCTCTA 400 nM
HAPBR CTGGAATTGCGATTTCTGGTAA 400 nM
HAPBprobe Cyan500-CGAGAATCACCCTGCCAGACTTCCGT-BBQ 100 nM
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multiplex assays and exact 95% confidence intervals are
provided.
Results
HPV EI Degenerate qPCR
In order to efficiently detect HPV types present in clinical
samples a broad spectrum E1 targeted Sybr green-based
degenerate assay was developed. Two primers were
selected from a highly conserved region of E1 region. To
test the ability of these primers to detect HPV DNA, they
were utilized in a qPCR assay using pHPV6, pHPV11,
pHPV16 or pHPV18 plasmid DNA as a template (Figure
1). A range of 106 to 101 copies/reaction of each full-
length HPV genome was used in the Sybr green qPCR
assay. There was a linear relationship between the Ct
values and cycle numbers for each of the plasmids when
a range of between 1 × 102 copies and 1 × 106 copies of
plasmid was present in the reaction, indicating that the
assay was quantitative and had a lower limit of detection
of 100 copies/reaction (Figure 1). Additionally, each stan-
dard had a similar curve indicating that all plasmids were
amplified with equal efficiency regardless of the HPV
type. This indicates that the degenerative Sybr Green-
based qPCR assay is a reliable method for quantitating
different types of HPV and should prove instrumental as
an adjunct assay for quantitation of HPV types not
detected by the multiplex qPCR assay (described in the
following section). Following, the assays are utilized in
140 specimen types that reflect the pathogenesis of HPV
in cutaneous and mucosal benign and malignant disease.
We have assayed 39 anogenital/cutaneous specimens, 25
cervical lavages from HIV positive women, 54 oral can-
cers from smoker drinkers and 22 from non smoker non
drinkers (Table 2).
Design of specific primers and probes for multiplex
detection of HPV types 6, 11, 16 and 18 by qPCR
To amplify and detect the most commonly detected
HPVs in mucosal disease type specific HPV, primers
and TaqMan probes were generated corresponding to
the L1 gene encoding the hypervariable V loop of the
major capsid protein (Figure 2). This sequence falls
within the region used for traditional PCR amplification
with MY09/11 and/or GP5+/6+ primer pairs. Sequence
alignment of the L1 gene with other oncogenic HPV
types was performed to aid in the selection of primers
and probes with maximum differences. Each HPV type-
specific TaqMan probe was synthesized with a unique
reporter dye at its 5′ end. Fluorophores for reporter
dyes were chosen that have the least overlap in their
excitation/emission spectra to minimize background
between detection channels.
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Figure 1 Degenerate “broad spectrum” HPV E1 primers detect HPV6, 11, 16 and 18. The E1 primer pair was used in a sybr green-based
qPCR assay to determine the performance of this primer pair to detect and quantitate HPV. Reactions were performed using genomic clones of
HPV6, 11, 16 or 18 as a standard curve that ranged from 1 × 106 to 1 × 102 copies and linear detection and quantitation of each amplicon was
observed.
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Table 2 Summary of patient tissues and fluids used for the detection of HPV
Sample Sample origin HPV (previously typed) HPV E1 qPCR HPV L1 qPCR
962046 anal virapap swab 11 + 11
950450 anal virapap swab 16 + 16
972696 anal virapap swab 33‡ + -
971380 anal virapap swab 35‡ + -
000699 anal virapap swab 40* + -
061675 anal virapap swab 45§ + -
983165 anal virapap swab 52‡ + -
972762 anal virapap swab 54 + -
972666 anal virapap swab 59§ + -
980280 anal virapap swab 69 + -
980520 anal virapap swab 73 + -
950474 anal virapap swab 83 + -
081673 anal virapap swab 89 + -
950472 anal virapap swab 16,53 + 16
950508 anal virapap swab 56,68§,84 + -
950504 anal virapap swab 6,11,18,26,33,45§,54,73 + 6,11,18
950496 anal virapap swab 6,16,45§,53,58‡,61,70§,83,84 + 6
071455 anal preservecyt swab 42 + -
071537 anal preservecyt swab 51 + -
071113 anal preservecyt swab 71 + -
071424 anal preservecyt swab 81 + -
963601 Cervical lavage 67‡ + -
950475 cervical virapap swab 6 + 6
950505 cervical virapap swab 18 + 18
950507 cervical virapap swab 26 + -
962678 cervical virapap swab 31‡ + -
950433 cervical virapap swab 32 + -
962047 cervical virapap swab 53 + -
950479 cervical virapap swab 54 + -
972833 cervical virapap swab 55* + -
962721 cervical virapap swab 66 + -
972835 cervical virapap swab 82 + -
971371 cervical virapap swab 84 + -
036465 cervical virapap cytobrush 58‡ + -
040670 cervical preservecyt swab 56 + -
CL1 Cervical lavage N/D - -
CL2 Cervical lavage N/D + 6/16
CL3 Cervical lavage N/D + -
CL4 Cervical lavage N/D - -
CL5 Cervical lavage N/D - -
CL6 Cervical lavage N/D + 6
CL7 Cervical lavage N/D + 6,18
CL8 Cervical lavage N/D - -
CL9 Cervical lavage N/D - -
CL10 Cervical lavage N/D - -
CL11 Cervical lavage N/D + -
CL12 Cervical lavage N/D - -
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Table 2 Summary of patient tissues and fluids used for the detection of HPV (Continued)
CL13 Cervical lavage N/D - -
CL14 Cervical lavage N/D - -
CL15 Cervical lavage N/D - -
CL16 Cervical lavage N/D - -
CL17 Cervical lavage N/D - -
CL18 Cervical lavage N/D + -
CL19 Cervical lavage N/D - -
CL20 Cervical lavage N/D - -
CL21 Cervical lavage N/D + 6
CL22 Cervical lavage N/D - -
CL23 Cervical lavage N/D + -
CL24 Cervical lavage N/D - -
CL25 Cervical lavage N/D - -
A1 S/D Oral biopsy N/D - -
A2 S/D Oral biopsy N/D - -
A3 S/D Oral biopsy N/D - -
A4 S/D Oral biopsy N/D - -
A5 S/D Oral biopsy N/D - -
A6 S/D Oral biopsy N/D - -
A7 S/D Oral biopsy N/D - -
A8 S/D Oral biopsy N/D - -
A9 S/D Oral biopsy N/D - -
A10 S/D Oral biopsy N/D - -
A11 S/D Oral biopsy N/D - -
A12 S/D Oral biopsy N/D - -
B1 S/D Oral biopsy N/D - -
B2 S/D Oral biopsy N/D - -
B3 S/D Oral biopsy N/D - -
B4 S/D Oral biopsy N/D - -
B5 S/D Oral biopsy N/D - -
B6 S/D Oral biopsy N/D - -
B7 S/D Oral biopsy N/D - -
B8 S/D Oral biopsy N/D - -
B9 S/D Oral biopsy N/D - -
B10 S/D Oral biopsy N/D - -
B11 S/D Oral biopsy N/D - -
B12 S/D Oral biopsy N/D + 16
C1 S/D Oral biopsy N/D - -
C2 S/D Oral biopsy N/D - -
C3 S/D Oral biopsy N/D - -
C4 S/D Oral biopsy N/D - -
C5 S/D Oral biopsy N/D - -
C6 S/D Oral biopsy N/D - -
C7 S/D Oral biopsy N/D - -
C8 S/D Oral biopsy N/D + 16
C9 S/D Oral biopsy N/D + 16
C10 S/D Oral biopsy N/D + 16
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Table 2 Summary of patient tissues and fluids used for the detection of HPV (Continued)
C11 S/D Oral biopsy N/D + 16
C12 S/D Oral biopsy N/D - -
D1 S/D Oral biopsy N/D - -
D2 S/D Oral biopsy N/D - -
D3 S/D Oral biopsy N/D - -
D4 S/D Oral biopsy N/D - -
D5 S/D Oral biopsy N/D - -
D6 S/D Oral biopsy N/D - -
D7 S/D Oral biopsy N/D - -
D8 S/D Oral biopsy N/D - -
D9 S/D Oral biopsy N/D - -
D10 S/D Oral biopsy N/D - -
D11 S/D Oral biopsy N/D - -
D12 S/D Oral biopsy N/D + 16
E1 S/D Oral biopsy N/D + 16
E2 S/D Oral biopsy N/D - -
E3 S/D Oral biopsy N/D - -
E4 S/D Oral biopsy N/D - -
E5 S/D Oral biopsy N/D - -
E6 S/D Oral biopsy N/D + 16
3 NS/ND Oral biopsy 16 N/D 16
4 NS/ND Oral biopsy 16 N/D 16
7 NS/ND Oral biopsy - N/D -
9 NS/ND Oral biopsy 16 N/D 16
12 NS/ND Oral biopsy 16 N/D -
13 NS/ND Oral biopsy 16 N/D 16
15 NS/ND Oral biopsy - N/D -
16 NS/ND Oral biopsy - N/D 18
18 NS/ND Oral biopsy - N/D -
20 NS/ND Oral biopsy - N/D -
21 NS/ND Oral biopsy 18 N/D -
23 NS/ND Oral biopsy 16 N/D -
27 NS/ND Oral biopsy - N/D -
32 NS/ND Oral biopsy - N/D -
35 NS/ND Oral biopsy 18 N/D 6/18
36 NS/ND Oral biopsy - N/D -
37 NS/ND Oral biopsy 18 N/D -
38 NS/ND Oral biopsy - N/D -
39 NS/ND Oral biopsy 18 N/D -
40 NS/ND Oral biopsy 16 N/D 16
51 NS/ND Oral biopsy 16 N/D 16
52 NS/ND Oral biopsy 16 N/D -
082481 Foot plantar wart 2 + -
082458 Foot plantar wart 57 + -
MX1 28 + -
MX2 64 + -
HPV6/11-related; *, HPV16-related; ‡, HPV18-related; §, N/D; not determined
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Derivation of standard curves for HPV type 6, 11,
16 and 18
As an initial step in the development of a HPV type-speci-
fic quantitative assay, plasmids containing type-specific
amplicons corresponding to the hypervariable V coding
region of the L1 gene were used to generate standard
curves in reactions containing a single HPV type primer
pair and probe. Copy number was determined based on
the size of each plasmid in nucleotide base pairs and cal-
culated assuming a single deoxynucleotide base pair has a
molecular weight of approximately 660 Daltons. Serial 10-
fold dilutions of each plasmids ranging from 2 × 101 to 2
× 106 plasmids/μl were made. Initially, plasmids were used
in qPCR assays containing a single HPV type-specific pri-
mer pair and probe and the Ct values were plotted against
cycle number to determine limits of sensitivity. There was
a linear relationship between the Ct values and cycle num-
bers when a range of between 2 × 101 copies and 2 × 106
copies of plasmid was present in the reaction, indicating
that the assay was quantitative and had a lower limit of
detection for each primer/probe combination of
20 copies/reaction (Figure 3A). These reactions were also
spiked with a mixture containing equal copy numbers (2 ×
104 copies) of each type-specific plasmids. In each type
specific qPCR assay, primers and probes were able to dis-
tinguish and quantitate between their respective type-spe-
cific HPV (2 × 104 copies) and the other HPV types (6 ×
104 copies) with minimal differences between the standard
curve and the type-specific HPV present in the mixture
(Figure 3B).
Primer/probe combinations detect specific types of HPV
L1 in multiplex reactions
To determine if standard curves could be obtained in
multiplex reactions, assays were performed on standard
curve plasmids that contained all 4 primer pairs and
probes. Linear plots of standards were similar in multi-
plex reactions compared to plots obtained when using
single primer pairs and probes indicating that type-spe-
cific amplification of individual standard curves was
unaffected by the presence of other type-specific primer
pairs and probes (Figure 4A). To determine if primers
Figure 2 Sequence and location of HPV type-specific L1 primers used for qPCR. The top line represents a schematic diagram of the HPV
L1 gene. Black boxes indicate the coding regions for the 5 hypervariable loop regions. The arrowheads indicate the position of the MY09/
11primer pair used in traditional nested PCR. The coding region for the hypervariable loop V region is expanded below the schematic. Shown is
an alignment of the HPV types identified in this study (HPV6, 11, 16 and 18) as well as other major oncogenic HPV types (HPV 31, 33, 45, 52, and
58). The type-specific primer sequences used for qPCR are underlined. Sequences corresponding to type-specific probes are boxed. Arrows
indicate the position and sequence of the GP5+/GP6+ primer pair used in traditional nested PCR.
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HPV6 L1 HPV11 L1
HPV16 L1 HPV18 L1
A
B
HPV6 L1 (Cy5)
2 X 10e4 HPV6 L1
2 X 10e4 HPV6,11,16,18 L1
HPV11 L1 (Texas Red)
2 X 10e4 HPV11L1
2 X 10e4 HPV6,11,16,18 L1
HPV16 L1 (FAM)
2 X 10e4 HPV16 L1
2 X 10e4 HPV6,11,16,18 L1
1 ng CaSki DNA L1
1 ng SiHA DNA L1
2 X 10e3 HPV16 L1
HPV18 L1 (Hex)
2 X 10e4 HPV18 L1
2 X 10e4 HPV6,11,16,18 L1
1 ng HeLa DNA L1
2 X 10e3 HPV18 L1
Figure 3 Standard curve and amplification plots obtained for single qPCR assays. (a) Reactions containing single type-specific primer pairs
and probes were performed on a serial dilution of purified plasmids to generate standard curves that show a linear relationship between copy
number and Ct value in a range from 2 × 101 to 2 × 106 copies/reaction. (b) Amplification plots for each excitation/emission spectrum are
shown for each reaction containing a single type-specific primer pair and probe. Arrows indicate the amplification plots for reactions containing
a mixture of each HPV type-specific L1 plasmid at 2 × 104 copies/reaction relative to the amplification plot corresponding to 2 × 104 copies for
each type-specific HPV L1 standard. Arrows in the HPV 16 and 18 type-specific L1 reactions also indicate the amplification plots of CaSki (HPV16),
SiHA (HPV16) and HeLa (HPV18) genomic DNA, respectively.
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Figure 4 The qPCR assay can specifically detect the HPV type L1 in a complex mixture containing all 4 L1 amplicons. (a) Individual
plasmids ranging from 2 × 101 to 2 × 106 copies were run in multiplex reaction mix to generate standard curves. (b) Multiplex reactions were
performed on mixtures containing all 4 plasmids carrying type-specific amplicons. Mixtures contained equal amounts of each plasmid ranging in
concentrations from 2 × 101 to 2 × 106 copies of each plasmid/reaction. The top panels show the standard curve amplification plots. The
bottom panel shows the amplification plots for each plasmid mixture concentration range. CaSki and HeLa cell DNA were used as positive
controls for HPV16 and 18, respectively. (c) Excess genomic DNA does not affect the performance of the multiplex HPV L1 qPCR assay. Reactions
were performed using a mixture containing all 4 HPV L1 plasmids that ranged from 2 × 106 to 2 × 101 copies. Additional reactions were
performed that contained a mixture of 5 × 105 copies of HPV6 L1, 5 × 104 copies of HPV11 L1, 5 × 103 copies of HPV16 L1 and 5 × 102 copies
of HPV18 L1. The assay was performed in the presence or absence of 100 ng of DG-75 DNA to determine if excess human genomic DNA would
affect the amplification and detection of type-specific HPV L1 DNA.
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and probes were specific for each type of HPV, reactions
were spiked with a mixture of all four plasmids at 2 ×
104 copies of HPV 6, 11, 16 and 18 L1 amplicons.
While there was nonspecific detection of some plasmids
at later times during the qPCR, the Ct values were well
beyond the Ct values for the lowest concentration of
each type-specific standard indicating that this detection
would not interfere with the specific quantitation of
each HPV type. If the multiplex qPCR was able to dif-
ferentiate between HPV L1 types then there would not
be significant deviation from the corresponding curve
for copy number in each type-restricted amplification of
the L1 gene. As was the case, addition of a mixture of
HPV L1 amplicons did not affect the ability of each pri-
mer/probe combination to specifically amplify the corre-
sponding type-specific L1 amplicon (Figure 4B).
Multiplex qPCR was also performed on a single mixture
of plasmids containing each of the L1 amplicon at a dif-
ferent concentration. There was good agreement in the
quantitation of individual type-specific amplicons in the
multiplex reactions and the predicted quantity of each
amplicon added to the assay. This indicated that in a
sample containing a mixture of four different HPV types
the multiplex qPCR assay was able to specifically detect
each type of HPV L1 gene.
In clinical samples an excess of cellular human DNA
would be present in the reaction. To determine if cellu-
lar DNA would affect the specific amplification of each
type of HPV, reactions containing a mixture of all four
plasmids ranging from 2 × 106 to 2 × 101 copies of
HPV 6, 11, 16 and 18 L1 amplicons were spiked with
100 ng of human genomic DNA obtained from the
HPV-negative human B-cell line, DG-75. The presence
of 100 ng of human cellular DNA did not affect the
amplification of the target HPV L1 gene compared to
unspiked controls in multiplex reactions (Figure 4C).
This suggests that the presence of excess human cellular
DNA would not affect the ability of the assay to specifi-
cally detect each type of HPV.
Use of the novel HPV qPCR assays in clinical specimens
Overall 140 clinical specimens that originate from the
oral cavity, skin and anogenital mucosa were assessed
(Table 2). Both biopsies and fluids have been tested. A
subset of specimens (anogenital/skin and oral cancers)
have been assessed by both standard assays and by the
novel assay.
Detection of HPV in well characterized anogenital
and skin lesions
The ability of the 2 qPCR assays to detect HPV in clini-
cal samples was assessed using DNA obtained from 35
well-characterized HPV-positive anogenital and skin
samples. The integrity of cellular DNA was confirmed
by analyzing Human Apolipoprotein B (HAPB) in each
of the samples, the minimum level of HAPB was 103
copies. The multiplex qPCR assay specifically detected
HPV6, 11, 16 or 18 in samples that had previously been
shown to contain these types (Table 2). Sample 950496
was determined to have multiple HPV types present
including HPV6 and HPV16 as determined by a nested
PCR line blot assay. While this sample was positive for
HPV6 by our multiplex qPCR assay it was negative for
HPV16. The difference in the ability of these 2 assays to
detected HPV16 in this sample may reflect the
decreased sensitive of our qPCR assay due the single
round amplification that is utilized. It should be noted
that HPV13+ and HPV32+ have been detected in other
clinical samples using the “broad spectrum” qPCR assay
(unpublished results) suggesting that the inability of the
assay to detect these 2 HPV types in their respective
samples was due to insufficient viral loads despite hav-
ing acceptable cellular HAPB levels.
HPV-type specific multiplex qPCR can detect and
quantitate HPV in cervical lavage samples from
HIV-positive individuals
DNA isolated from 25 cervical lavage samples obtained
from HIV-positive women was used to determine if the
multiplex qPCR assay could be used to detect the 4
most common HPV types in gynecological samples
(Table 2) and to quantitate these viral loads (Table 3).
Samples were deemed positive for HPV if their copy
number was ≥103 as previously described [17]. HPV
DNA was detected in 5/25 samples in the 6, 11, 16, 18
multiplex assay. Both HPV6 and HPV16 were detected
in two of the 25 samples tested (Table 3). One sample
was positive for both HPV6 and 18, another sample was
positive for HPV18 only, and one sample was positive
for HPV6 only. All of these samples were also positive
for HPV using a Sybr Green-based qPCR assay that uti-
lizes degenerative “broad spectrum” primers targeting
the E1 gene, additionally 3 samples were detected that
did not harbor HPV types 6,11,16 or 18. Thus 8/25 cer-
vical samples were HPV-positive using the E1 broad
spectrum assay (Table 2 and Table 3). These results are
consistent with the finding that multiple HPV types are
commonly found in cervical samples [23]. Additionally,
three of the samples that were not positive for the 4
HPV types used in the multiplex assay were positive for
HPV using the Sybr Green-based qPCR assay indicating
that HPV types different than 6, 11, 16 and 18 were pre-
sent in these samples. Sequence analysis of the EI pro-
ducts also detected types 35, 44, 67 and 68 (Table 3).
HPV-type specific multiplex qPCR can detect and
quantitate HPV in oral cancers
Recent evidence has suggested that HPV plays a role in the
development of oral cancers [5-7,24]. In contrast to cervical
infections with HPV where multiple HPV types have been
detected simultaneously, most oral infections involve a
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single type of HPV [23]. To determine whether HPV is
associated with oral cancer, archived oral cancer tissue
samples were obtained from the UNC Healthcare Cancer
Registry. These samples were divided into two groups
according to the patients smoking/drinking history.
Because HPV associated cancers have a proclivity for dis-
tinct regions of the oral cavity, the location of the cancers
is identified in Table 4. DNA obtained from the paraffin-
embedded tissue was used in multiplex reactions to assess
the ability of the qPCR assay to detect and quantitate HPV
Table 3 Summary of multiplex HPV L1 qPCR and sybr green-based E1 qPCR assays
Multiplex TaqMan Reaction Sybr Green Reaction
Specimen Location HPV6 L1 HPV11 L1 HPV16 L1 HPV18 L1 HPV E1 HPV E1 sequence
CL2 Cervix 3.72E+05 0.00E+00 2.51E+04 0.00E+00 4.62E+06 mult HPV types
CL3 Cervix 1.00E+00 0.00E+00 1.00E+00 4.29E+04 2.31E+06 HPV44
CL6 Cervix 4.23E+05 0.00E+00 4.27E+04 0.00E+00 7.05E+06 HPV67
CL7 Cervix 6.30E+04 0.00E+00 1.00E+00 9.76E+03 5.10E+01 N/D
CL11 Cervix 1.00E+00 0.00E+00 1.00E+00 1.40E+01 4.73E+03 HPV35
CL18 Cervix 1.34E+02 0.00E+00 1.00E+00 4.00E+01 6.03E+04 mult HPV types
CL21 Cervix 3.27E+04 1.00E+00 2.82E+02 1.40E+01 2.11E+06 HPV68
CL23 Cervix 2.67E+02 4.00E+01 1.00E+00 4.00E+01 4.21E+04 mult HPV types
Table 4 Anatomical location of oral cancer tissue used for the extraction of genomic DNA
Smoker/Drinker oral cancer samples Non-smoker/non-drinker oral cancer samples
Sample Site Sample Site Sample Site
A1 OC C4 OC-gingiva 3 BOT
A2 HP C5 larynx-TVC 4 BOT
A3 OC C6 OC-RMT 7 BOT
A4 OC C7 OC-gingiva 9 BOT
A5 OC C8 OC-gingiva 12 BOT
A6 OC C9 OP-BOT 13 BOT
A7 OC C10 OP-tonsil 15 Tongue
A8 OC C11 OC 16 Tongue
A9 OC C12 larynx-supraglottis 18 Tonsil
A10 OC D1 larynx-glottis 20 Tongue
A11 OC D2 OP-tonsil 21 Tongue
A12 OC D3 larynx-supraglottis 23 Tongue
B1 HP D4 HP- post wall 27 Tongue
B2 Larynx D5 larynx-epiglottis 32 Tongue
B3 OP-BOT D6 OP-soft palate 35 Tonsil
B4 Larynx D7 OC-tongue 36 Tonsil
B5 OC-tongue D8 OC-tongue 37 Tonsil
B6 HP-pyriform D9 HP-pyriform 38 Tonsil
B7 OC-RMT D10 OP-tonsil 39 Tonsil
B8 OC-FOM D11 OC-RMT 40 Tonsil
B9 OP-buccal D12 OP-tonsil 51 BOT
B10 OC-gingiva E1 HP-pyriform 52 BOT
B11 larynx-TVC E2 OC-tongue
B12 OP-BOT E3 OP-FOM
C1 OP-BOT E4 OC-gingiva
C2 OC-gingiva E5 larynx-epiglottis
C3 larynx-glottis E6 OC-tongue
BOT; base of tongue, FOM; floor of mouth, HP; hypopharynyx, OC; oral cavity, OP; oropharynyx, RMT; retromolar trigone, TVC; true vocal cord.
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in clinical samples. Samples were considered positive for a
specific HPV type if the copy number was ≥1000 copies
[17].
Initially, the multiplex qPCR assay was performed on
54 oral cancer samples from the population of patients
with a history of smoking/drinking. Of these 54 samples,
8 (15%) had >1000 copies of HPV16/μg total DNA and
were considered positive for HPV16 (Table 5).
This percentage is consistent with other published
reports of HPV detection in oral cancer in individuals
who are smokers or drinkers [7]. None of the samples
were positive for HPV6, 11 or 18. Type-specific single-
plex reactions were performed on HPV16 positive sam-
ples to assess the specificity of the multiplex assay to
identify specific HPV types (Table 5). All 7 HPV 16
multiplex positive samples were also positive for HPV16
DNA when assayed by the singleplex reactions. None of
the samples were positive for HPV6, 11 or 18 in single-
plex reactions indicating that specificity of the multiplex
reaction and singleplex reaction were comparable.
Detection of cellular HAPB in these samples reveal that
they contained similar amounts of amplifiable cellular
DNA. This sample set was also subjected to E1 broad
spectrum PCR and only those that were positive for
HPV 16 in the other assays were detected as positive.
Unlike the cervical samples, other HPV types were not
detected in these oral cancers. Similar HPV16 copy
numbers were obtained from the multiplex reactions
and E1 broad spectrum qPCR, compared to singleplex
reactions indicating that both multiplex qPCR and E1
broad spectrum provided a reliable assessment of
HPV16 copy number in these samples (Table 5).
HPV is often detected in the oral cancers of non-smo-
ker/non-drinker (NS/ND) patients [24]. To assess the
performance of the multiplex qPCR assay to detect and
differentiate between the 4 types of HPV, multiplex
qPCR was performed using DNA obtained from oral
cancers of non-smoker/non-drinkers that have pre-
viously been typed by sequencing products derived from
degenerate PCR. These samples represent a cohort of
non-smoker/non-drinker patients [24] who were either
histologically diagnosed with head and neck cancer, or
were at risk for recurrence (previous oral cancer/pre-
viously diagnosed). The site of the malignancy is
detailed in Table 4. For follow up patients previously
diagnosed with oral cancer a new biopsy at the site of
the previous cancer was obtained. Samples were consid-
ered HPV-positive if their HPV copy number was above
1000 copies/μg of total DNA. Seven non-smoker/non-
drinker cancer subjects were positive for HPV16 or 18
by multiplex qPCR. Six of the subjects (27%) tested
positive for HPV16 while 2 subjects (9%) tested positive
for HPV18 by multiplex qPCR (Figure 5). There was
one subject who tested positive for both HPV6 and 18
by multiplex qPCR. Fifty seven percent of biopsies that
were taken from invasive cancers (n = 14) were positive
for either HPV16 or HPV18. Of the cancer biopsies 6
were positive for HPV16 while 2 were positive for
HPV18. There were some discrepancies between HPV
detection by nested PCR versus the multiplex qPCR
assay. While 57% of cancers were positive using the
multiplex analysis, 77% of cancers were positive using
the nested PCR detection method. However, the 2
assays were run using DNA isolated from different sec-
tions of the same paraffin block. As viral distribution
within the tissue may not have been homogeneous; this
may account for differences in HPV detection by the 2
assays. Alternatively, the nested PCR while not quantita-
tive may be inherently more sensitive due to second
round of amplification during the nested PCR. Despite
these discrepancies, there was reasonable concordance
in the type-specific HPV identified in oral cancer biop-
sies by the qPCR assay compared with previous typing
obtained by traditional MY9-MY11 L1 nested PCR fol-
lowed by direct sequencing of the amplicons [24]. Type
determination by the qPCR assay was concluded upon
detection of a clear abundance of a specific type of HPV.
In summary, we compared our novel qPCR assay,
which is a combination of E1 and L1 PCR results, to the
gold standard method of “previously typed HPV” ano-
genital and oral cancer specimens (Table 2). Previously
typed anogenital and skin specimens were typed using a
Table 5 Similar HPV16 copy number are obtained from multiplex and individual HPV type-specific singleplex qPCR
assays and universal E1 qPCR assay
Sample Site HAPB Multiplex
HPV6 L1
Multiplex
HPV11 L1
Multiplex
HPV16 L1
Multiplex
HPV18 L1
Singleplex
HPV6 L1
Singleplex
HPV11 L1
Singleplex
HPV16 L1
Singleplex
HPV18 L1
HPV
E1
B12 OC 4.01e5 0 0 5.27e5 2.50e2 1.43e2 0 3.66e5 6.65e2 4.17e5
C9 HP 4.32e5 0 0 1.65e6 0 1.74e2 0 2.84e6 0 2.04e6
C10 OC 3.68e5 0 0 1.15e6 0 5.61e2 0 2.39e6 9.87e2 1.21e6
C11 OC 2.54e5 0 0 3.22e4 2.50e2 0 2.35e2 2.35e4 5.15e2 4.65e3
D12 OC 6.38e5 0 0 1.53e7 0 1.60e2 0 0.90e7 0 1.04e7
E1 OC 3.07e5 0 0 0.98e5 2.5e2 7.15e2 0 1.78e5 3.22e2 2.37e4
E6 OC 8.39e5 0 0 2.08e5 0 0 0 5.95e5 0 3.33e5
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standard PCR performed using MY09/MY11 consensus
HPV L1 primers. Following PCR, specimens were typed
by hybridizing to 29 different HPV types as well as 10
additional types together in a probe mixture as pre-
viously described [3]. In this instance, the concordance
was absolute, leading to a sensitivity of 100% (91.0%,
100%). Oral cancer specimens, however were previously
typed using nested PCR MY09/MY11 followed by GP5
+/6+ and sequencing of the PCR product [24]. The sen-
sitivity of the novel assays compared to this method was
53.9% (25.1, 80.1%). Specificity was determined by com-
parisons to true negatives as determined by the gold
standard assays. It was determined that the specificity
was 88.9%. Utilizing the data generated in Table 2, we
detected an overall sensitivity of 89% (95% CI: 77% -
96%) and specificity of 90% (95%CI: 52% - 98%).
Discussion
The causal relationship between oncogenic HPV and
malignancy indicates the importance of being able to
quickly detect and quantify specific HPV types when it
is suspected that a lesion may harbor an HPV infection.
This would aid in the assessment of precancerous
lesions and impact on the decision to treat the lesion
before it progressed to a more severe form of disease or
allow the lesion to resolve on its own. In addition, low
risk types of HPV also impact negatively on quality of
life indicating the importance of tracking and identifying
HPV types involved in the development of warts. Assays
that are capable of distinguishing between common
types of HPV responsible for cancers as well as those
involved in the development of warts would facilitate
the understanding of HPV epidemiology and pathology.
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Figure 5 Type-specific L1 DNA determined by multiplex qPCR correlates with typing determined by degenerative PCR using DNA
from nonsmoker/nondrinker clinical samples. DNA was extracted from paraffin-embedded tissue and used in the HPV type-specific L1 qPCR
assay. C indicates the presence of cancer, P indicates that cancer was previously diagnosed and B indicates the tissue was histologically benign
at the time biopsies were performed. The type-specific HPV L1 for each sample was previously determined by nested PCR using MY09/11 and
GP5+/6+ primers pairs followed by direct sequencing of the PCR products. Homology of the PCR product with HPV16 is indicated by 16 while
homology of the PCR product with HPV18 is indicated by 18. The inability to obtain a product by nested PCR is indicated by a dash. HPV type
as determined by qPCR.
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In order to do so, two qPCR assays were developed for
use in tandem. An E1 degenerate broad spectrum Sybr
green-based assay was developed that would detect any
HPV. In addition, the real-time qPCR that utilizes speci-
fic TaqMan probes labeled with different fluorophores
represented an attractive method for quickly identifying
and quantifying the presence of multiple viruses in a
single sample, simultaneously, [25] and could be adapted
to type-specific detection of HPV. Multiplexing such a
reaction reduced the possibility of introducing errors
inherent in performing multiple single type specific
reactions for an individual sample, it also reduced the
amount of time and reagents required to perform the
assay. This would reduce the cost of performing the
reaction thus making the assays more cost effective and
increasing the accessibility of the assay to the applica-
tion of clinical samples in general. While comparable L1
MY09/MY11 degenerate priming, these 1-step single
tube qPCR assays have the additional advantage of being
high throughput allowing for the detection of HPV in a
a large number of samples in a relatively short amount
of time when compared to the standard assay involving
nested PCR followed by hybridization.
Assays were developed that detect HPV types 6, 11, 16
and 18; types targeted by the prophylactic quadrivalent
vaccine. Each type-specific TaqMan probe contained a
fluorophore that differed significantly in its excitation/
emission spectra compared to other type-specific probes
in the assay, and worked with equal efficiency allowing
for the detection of multiple probes in a single reaction
tube and reducing the time and reagents necessary to
perform multiple individual reactions. The presence of
large amounts of cellular genomic DNA did not affect
the specific amplification and detection of amplicons.
This assay had a linear range of detection over 6 orders
of magnitude, allowing identification/typing of viral gen-
omes and detection of viral load [11]. A recent study
performed to determine HPV 6, 11, 16 and 18 seropre-
valence in the US determined that many sexually active
females become exposed to these HPV types, suggesting
that continued evaluation is warranted to determine the
impact of vaccination[26]. The qPCR assays described
here may be instrumental in determining the efficacy of
the quadrivalent HPV vaccine, particularly in vulnerable
patients and will be instrumental in investigating HPV
epidemiology in longitudinally collected samples.
Increasing oncogenic HPV viral loads have been asso-
ciated with development of malignancy [9]. While to
our knowledge these associations have not yet been
determined for other HPV associated non malignant
conditions, it is reasonable to expect that viral loads pre-
cede disease development in that realm as well. These
assays may be of significant use in deciphering the
importance of HPV replication prior to disease
development. The use of these qPCR assays have signifi-
cant utility in distinguishing the presence of specific
types of HPV. The one tube multiplex assay containing
type/fluorophore specific TaqMan probes directed
against HPV 6,11,16 and 18 provides a quick reliable
method of distinguishing between HPV types and quan-
titating viral load while minimizing reagent costs and
reducing errors.
In cases where other HPV types are involved, the
“broad spectrum” HPV qPCR assay is instrumental in
detection of HPV types that may be present but are not
detected by the multiplex assay. While HPV16 and 18
have been shown to be responsible for the majority of
HPV-related cancers, there are additional oncogenic
types of HPV involved in malignancy. We used E1
degenerate primers in a sybr green-based qPCR assay
that could amplify all HPV types. The E1 consensus
region is approximately 150-200 bp, and is much more
amenable to real time qPCR than the MY11-MY9 region
which is 600 bp. To date, we are unaware of other pri-
mers sets used for HPV degenerate qPCR, however, the
L1 based spf1/2 primers could serve as an alternative
[27]. These primers generate a 65 bp fragment and have
been used to detect 43 types of HPV in a hybridization
line assay. The E1 assay is truly broad spectrum and
was capable of detecting and quantitating 35 cutaneous
and mucosal HPV types including HPV6, 11, 16 and 18
from previously characterized clinical specimens and
provides an additional assay to augment the multiplex
qPCR assay. Table 3 and 5 highlights the fidelity of
these complimentary methods and clearly illustrates that
in HPV 16 positive oral cancer samples, that were by
multiplex were also positive by both singleplex and E1
broad spectrum assay. Further, similar levels of HPV 16
were detected by each of these methods. We have
shown that we consistently detect the same range of
HPV types as the standard MY09/11 and gp5+/6+. The-
oretically we can detect more types because we are not
limited to HPV types available on pre-blotted mem-
branes used for hybridization.
The ability to detect and quantify specific HPV types in
clinical samples allows for assessment of HPV-related dis-
ease. While used on cloned DNA/plasmids for types
6,11,16 and 18, the multiplex assay also performed opti-
mally on well-validated anogenital and skin specimens.
Our test shows both high sensitivity and specificity 89%
and 90%, but it should be noted that the specificity esti-
mate is based on only 9 true negatives, and thus, has a
large confidence interval. Our sensitivity estimate’s narrow
confidence interval indicates that the true sensitivity of
our test is likely higher than 77%. Takac et al [18] in their
development of a realtime assay that detected 15 onco-
genic and 5 low risk risk HPV types also had similar levels
of sensitivity and specificity (95.45% and 91.57%,
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respectively). Among the clinical isolates there were HPV
types 31, 33, 52,58, 67 and 35, not cross reactivity was
detected with HPV 16. Likewise clinical isolates with HPV
types 45, 59 did not cross react with HPV 18 nor did HPV
55 cross react with HPV 6/11 nor did HPV 6 cross react
with 11 (Table 2, related types are indicated by symbols,
Figure 4B and 4C). This highlights the specificity of the
assay. There was nearly 100 percent agreement with
regard to detection of HPV 6, 11, 16 and 18 and no cross
reactivity with other types although there was disagree-
ment in one of the specimens. Multiple HPV types includ-
ing HPV 6 and 16 had previously been detected in sample
950496 using a nested PCR/line blot technique. While
HPV 6 was detected by our multiplex assay, HPV16 was
not detected. This discrepancy may be due to levels of
HPV16 below the level required for detection by our
qPCR assay. Compared to traditional nested PCR, the real
time qPCR assays described here were able to distinguish
between specific mucosal types of HPV and also had the
added benefit of quantitating viral loads in cervical lavages
and in head and neck tissue biopsied from a small cohort
of oral cancer patients with high risk factors (smoking/
drinking) as well as from non-smoker/non-drinker cancer
patients. In the HIV-positive women approximately 31%
of the cervical fluids were HPV-positive with multiple con-
current HPV infections. Interestingly, in the oral cancer
group that had a history of smoking and/or drinking, only
15% of subjects were positive for HPV. In contrast onco-
genic HPV could be detected in almost all of the cancer
subjects in the non-smoking/non-drinking group suggest-
ing that HPV plays a significant role in the development of
oral cancers in the absence of additional risk factors. This
is consistent with findings from this lab as well as others,
showing low rates of oncogenic HPV infection in oral can-
cers of smoker/drinkers and high rates of infection in oral
cancers obtained from non-smoker/non-drinkers [24,28].
With real time PCR technology becoming an increas-
ingly common technology for clinical labs, this assay will
allow for the rapid identification and quantification of
pathogenic types of HPV. As viral replication often pre-
cedes the development of virus-associated pathology, the
ability to quantitate HPV in persons ‘at risk’ for HPV
associated disease may be an informative prognostic indi-
cator. The novel qPCR assays described here may provide
insight into the epidemiology and natural history of HPV
infections within individuals and groups, providing prog-
nostic capability and leading to the development of inter-
vention strategies to prevent disease progression.
Conclusions
We developed a single tube real time PCR assay capable
of differentially detecting and quantifying 4 types of
HPV represented in an FDA approved vaccine, types
6,11,16, and 18.
The ability of the assay to distinguish between these 4
types of HPV in a complex mixture of DNA and in the
presence of human genomic DNA was validated. A
“broad spectrum” sybr green-based qPCR assay that uti-
lizes E1 degenerate primers that is capable of detecting
multiple HPV types was also developed and validated.
We showed that our assays performed as well as tradi-
tional nested PCR followed by sequencing/hybridization
in distinguishing between different types of HPV in ano-
genital and oral fluids and tissues from high risk/dis-
eased subjects.
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